ANGIOTECH ANNOUNCES VASCULAR WRAP/LIFESPAN VASCULAR GRAFT COMBINATION PRODUCT RECEIVES DESIGNATION OF 'DEVICE' FOR U.S. PIVOTAL STUDY

Angiotech Pharmaceuticals, Inc. today announced that its Vascular Wrap Paclitaxel-Eluting Mesh/Lifespan Vascular Graft has received a designation of "device" from the Office of Combination Products at the U.S. Food and Drug Administration (FDA). This designation of "device" has historically indicated a faster regulatory and commercial timeline for a product as compared to when the FDA considers a combination product to be a "drug".

Yahoo News (http://biz.yahoo.com/prnews/051220/to039.html?.v=17)